1.51
-0.05 (-3.21%)
| Previous Close | 1.56 |
| Open | 1.53 |
| Volume | 7,428,611 |
| Avg. Volume (3M) | 12,499,141 |
| Market Cap | 961,746,176 |
| Price / Sales | 8.59 |
| Price / Book | 3.59 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -119.54% |
| Operating Margin (TTM) | -42.18% |
| Diluted EPS (TTM) | -0.210 |
| Quarterly Revenue Growth (YOY) | 12,927.30% |
| Total Debt/Equity (MRQ) | 45.40% |
| Current Ratio (MRQ) | 7.86 |
| Operating Cash Flow (TTM) | -204.34 M |
| Levered Free Cash Flow (TTM) | -142.38 M |
| Return on Assets (TTM) | -16.07% |
| Return on Equity (TTM) | -45.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Geron Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.63 |
|
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.09% |
| % Held by Institutions | 81.21% |
| 52 Weeks Range | ||
| Median | 1.50 (-0.66%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Scotiabank | 08 May 2025 | 1.50 (-0.66%) | Hold | 1.26 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Jun 2025 | Announcement | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 28 May 2025 | Announcement | Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program |
| 19 May 2025 | Announcement | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 07 May 2025 | Announcement | Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights |
| 18 Apr 2025 | Announcement | Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 31 Mar 2025 | Announcement | Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |